ADO-TRASTUZUMAB EMTANSINE - Food and Drug Administration

Set ID
f13c9ced-2bd3-4dc2-aa1a-5bdacbc77671
Type
Indexing - product concept
Effective date
2019-07-31
Version
1
Source
DailyMed source

Mapped DailyMed Labels#

Label, Relation, Manufacturer table
LabelRelationManufacturerEffective
These highlights do not include all the information needed to use KADCYLA safely and effectively. See full prescribing information for KADCYLA. KADCYLA ® (ado-trastuzumab emtansine) for injection, for intravenous use Initial U.S. Approval: 2013Product nameGenentech, Inc. | Genentech, Inc. (Hillsboro) | F. Hoffmann-La Roche AG | Roche Diagnostics GmbH | Lonza Biologics Tuas Pte Ltd. | Roche Singapore Technical Operations Pte. Ltd2026-04-01
These highlights do not include all the information needed to use KADCYLA safely and effectively. See full prescribing information for KADCYLA. KADCYLA ® (ado-trastuzumab emtansine) for injection, for intravenous use Initial U.S. Approval: 2013Product nameGenentech, Inc. | Genentech, Inc. (Hillsboro) | F. Hoffmann-La Roche AG | Roche Diagnostics GmbH | Lonza Biologics Tuas Pte Ltd. | Roche Singapore Technical Operations Pte. Ltd2025-11-21